Group 1 - Cathie Wood's ARK Innovation ETF (ARKK) is down 16.73% this year, making it the second-worst actively traded U.S. diversified stock fund [1] - The ARK Innovation portfolio is underperforming significantly compared to the S&P 500, which is nearing all-time highs [2][4] - Nearly 70% of the 35 stocks in the ARK Innovation portfolio are down this year, with three stocks down 60% or more [3] Group 2 - Pacific Biosciences of California (PACB) has seen its shares decline nearly 81% this year, the worst performance in the ARK Innovation portfolio [5] - Tesla (TSLA), the largest position in the ARK Innovation portfolio at over 11.4%, is down nearly 28% this year [7] - Critics argue that ARK Innovation's approach lacks adequate risk management, leading to significant pain when stocks underperform [8] Group 3 - The worst-performing stocks in the ARK Innovation portfolio include Pacific Biosciences, Verve Therapeutics (down 62.2%), Ginkgo Bioworks (down 60.2%), 10x Genomics (down 59.5%), and Unity Software (down 52.5%) [11]
Why Cathie Wood Thinks Stock Fears Are At 'Depression' Levels